Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel

PHASE4CompletedINTERVENTIONAL
Enrollment

577

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

January 30, 2020

Study Completion Date

August 30, 2022

Conditions
Influenza
Interventions
BIOLOGICAL

Flublok™ Quadrivalent by Sanofi, Inc.

0.5 mL intramuscular dose of Flublok

BIOLOGICAL

VaxigripTetra™ by Sanofi, Inc.

0.5 mL intramuscular dose of Vaxigrip

Trial Locations (2)

Unknown

Soroka Medical Center, Beersheba

Rabin Medical Center-Beilinson, Petah Tikva

All Listed Sponsors
collaborator

Abt Associates

INDUSTRY

collaborator

Clalit Research Institute

OTHER

collaborator

Soroka University Medical Center

OTHER

collaborator

Rabin Medical Center

OTHER

collaborator

University of Michigan

OTHER

lead

Centers for Disease Control and Prevention

FED